Why Iovance Biotherapeutics (IOVA) Stock Is Down Today

Iovance Biotherapeutics (IOVA) is down 35.9% today. Here is some analysis on what might have caused this price movement. ([nasdaq.com](https://www.nasdaq.com/press-release/iovance-reports-updated-iov-lun-202-results-and-adds-precision-til-strategy-second?utm_source=openai))

Analysis: The sell-off appears tied to investors digesting the company’s full Phase 2 lung cancer update and deciding the broader dataset was not strong enough to justify the stock’s recent run-up. While management highlighted a high-response biomarker-selected subgroup, the headline response rate in the overall study population was largely unchanged from prior data, and the new precision strategy still needs prospective validation. ([nasdaq.com](https://www.nasdaq.com/press-release/iovance-reports-updated-iov-lun-202-results-and-adds-precision-til-strategy-second))

Details:

Iovance reported a 24.6% objective response rate in 69 patients with non-squamous metastatic NSCLC, which was described as consistent with the previously reported 25.6% rate in 39 patients. ([nasdaq.com](https://www.nasdaq.com/press-release/iovance-reports-updated-iov-lun-202-results-and-adds-precision-til-strategy-second))

The company emphasized a retrospective biomarker-enriched subgroup with a 59.1% response rate, but that subgroup included 22 patients and was identified after the fact rather than through prospective enrollment. ([nasdaq.com](https://www.nasdaq.com/press-release/iovance-reports-updated-iov-lun-202-results-and-adds-precision-til-strategy-second))

Iovance said it plans to begin enrolling the new POSITILITY biomarker-enriched cohort in November 2026, suggesting the precision approach is still in an earlier validation stage. ([nasdaq.com](https://www.nasdaq.com/press-release/iovance-reports-updated-iov-lun-202-results-and-adds-precision-til-strategy-second))

The stock had jumped after the initial October 28 announcement, then reversed sharply once the webcast and fuller data details were released, which fits a sell-the-news reaction after elevated expectations. ([za.investing.com](https://za.investing.com/news/stock-market-news/why-is-iovance-biotherapeutics-stock-sliding-today-93CH-4534932?utm_source=openai))

Sources:

GlobeNewswire, Nasdaq, Investing.com, Finviz

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$IOVA Hedge Fund Activity

We have seen 167 institutional investors add shares of $IOVA stock to their portfolio, and 98 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

INVENOMIC CAPITAL MANAGEMENT LP removed 7,012,956 shares (-82.5%) from their portfolio in Q2 2026, for an estimated $29,173,896
BLACKROCK, INC. added 5,877,176 shares (+18.9%) to their portfolio in Q2 2026, for an estimated $24,449,052
TWO SIGMA INVESTMENTS, LP added 5,323,264 shares (+38.9%) to their portfolio in Q2 2026, for an estimated $22,144,778
JUPITER ASSET MANAGEMENT LTD added 4,535,080 shares (+inf%) to their portfolio in Q2 2026, for an estimated $18,865,932
DIMENSIONAL FUND ADVISORS LP added 3,814,747 shares (+144.2%) to their portfolio in Q2 2026, for an estimated $15,869,347
GOLDMAN SACHS GROUP INC removed 3,663,726 shares (-41.8%) from their portfolio in Q2 2026, for an estimated $15,241,100
BANK OF AMERICA CORP /DE/ removed 3,496,535 shares (-41.2%) from their portfolio in Q2 2026, for an estimated $14,545,585

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.